Incidence of heart failure in relation to QRS duration during antihypertensive therapy: The LIFE study

Journal of Hypertension

Volumn 27, Issue 11, 2009, Pages 2271-2277

  Okin, Peter M ^a   Devereux, Richard B ^a   Kjeldsen, Sverre E ^b,c   Edelman, Jonathan M ^d   Dahlöf, Björn ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Electrocardiography; Heart failure; Hypertension; Prognosis

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL;

EID: 73249116582     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328330b66b     Document Type: Article

References (38)

1. Dhingra R, Nam BH, Benjamin EJ, Wang TJ, Larson MG, D'Agostino RB, et al. Cross-sectional relations of electrocardiographic QRS duration to left ventricular dimensions. J Am Coll Cardiol 2005; 45:685-689.
2. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE Study. J Hypertens 2001 ; 19:1883-1891. (Pubitemid 32924957)
3. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005; 46:2183-2192. (Pubitemid 41785483)
4. Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J, Nori D, Kaatz S, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002; 122:528-534. (Pubitemid 35002131)
5. Dhingra R, Pencina MJ, Wang TJ, Nam B-H, Benjamin EJ, Larson MG, et al. Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. Hypertension 2006; 47:861-867. (Pubitemid 44297556)
6. Sandhu R, Bahler RC. Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular dysfunction. Am J Cardiol 2004; 93:244-246. (Pubitemid 38058744)
7. Shamim W, Yousufuddin M, Cicoria M, Gibson DG, Coats AJS, Henein MY. Incremental changes in QRS duration in serial ECGs over time identify high risk elderly patients with heart failure. Heart 2002; 88:47-51. (Pubitemid 34665000)
8. Luliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN, for the Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002; 143:1085-1091.
9. Bruch C, Gotzmann M, Stypmann J, Wenzelburger F, Rothenburger M, Grude M, et al. Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure: incremental prognostic value of QRS duration and a restrictive mitral filling pattern. J Am Coll Cardiol 2005; 45:1072-1075. (Pubitemid 40432441)
10. Triola B, Olson MB, Reis SE, Rautaharju P, Bairey Merz CN, Kelsey SF, et al. Electrocardiographic predictors of cardiovascular outcome in women. The National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol 2005; 46:51-56. (Pubitemid 40905129)
11. Yerra L, Anavekar N, Skali H, Zelenkofske S, Velazquez E, McMurray J, et al. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006; 3:313-316. (Pubitemid 43264408)
12. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002; 106:3068-3072. (Pubitemid 35440290)
13. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562. (Pubitemid 26154241)
14. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35:1628-1637. (Pubitemid 30307510)
15. Arnold JMO, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, et al. Prevention of heart failure in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:1284-1290. (Pubitemid 36314412)
16. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, Shlipak MG. Predictors of heart failure among women with coronary disease. Circulation 2004; 110:1424-1430. (Pubitemid 39263737)
17. Fagard RH, Staessen JA,Thijs L, Cells H, Birkenhäger WH, Bulpitt CJ, et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004; 44:459-464. (Pubitemid 39281496)
18. lngelsson E, Sundström J, Ärnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294:334-341.
19. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-1621. (Pubitemid 32947523)
20. Okin PM, Devereux RB, Harris KE, Jem S, Kjeldsen SE, Julius S, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with decreased heart failure hospitalization in hypertensive patients. Ann Intern Med 2007; 147:311-319. (Pubitemid 351664558)
21. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
22. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Bergek G, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278:212-216. (Pubitemid 27339586)
23. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of different blood-pressure lowering regimens of major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
24. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003; 289:2534-2544.
25. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlöf B, et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004; 43:1029-1034. (Pubitemid 38579909)
26. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan vs atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 2003; 108:684-690. (Pubitemid 36999252)
27. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events. JAMA 2004; 292:2343-2349. (Pubitemid 39491918)
28. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
29. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992; 20:1180-1186.
30. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25:417-423.
31. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37:161-186.
32. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standard and Procedures for Measurement and Classification. Bristol, England: John Wright PSG Inc.; 1982. pp. 111-130, 227.
33. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimate. Am Stat 2005; 59:301-307. (Pubitemid 41616828)
34. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the LIFE Study. Hypertension 2007; 50:984-990.
35. Eriksson P, Hansson P-O, Eriksson H, Dellborg M. Bundle-branch block in a general male population: the study of men born 1913. Circulation 1998; 98:2494-2500.
36. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43:2207-2215.
37. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction inessential hypertension: prevalence, determinants and prognostic value. Hypertension 2005; 45:412-418. (Pubitemid 40326250)
38. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2001; 37:1042-1048. (Pubitemid 32217604)